ch.oddb.org
 
Apotheken | Arzt | Interaktionen | Medikamente | MiGeL | Services | Spital | Zulassungsi.
Fachinformation zu Clofibrat Tripharma®:Tripharma AG, Uznach
Vollst. FachinformationDDDDrucken 
Gal.Form/Ther.Gr.Zusammens.Eigensch.Pharm.kinetikInd./Anw.mögl.Dos./Anw.Anw.einschr.Unerw.Wirkungen
Interakt.Überdos.Sonstige H.Swissmedic-Nr.Stand d. Info. 
C10AB01 - ClofibrateATC-DDD Version 2016. Source: WHO
C - Cardiovascular System

This group comprises substances used for the treatment of cardiovascular conditions.
Drugs used for the treatment of hypertension are classified in C02 - Antihypertensives, C03 - Diuretics, C07 - Beta blocking agents, C08 - Calcium channel blockers, and C09 - Agents acting on the renin-angiotensin system. For the classification of combination products of antihypertensives from different ATC groups, the following ranking should be used, from higher to lower precedence: C09, C07, C08, and C03.

C10 - Lipid Modifying Agents
 

The DDDs are based on the treatment of hypercholesterolemia.

C10A - Lipid Modifying Agents, plain

Pantethine, which is also used in the treatment of hyperlipidemi, is classified as a vitamin in A11HA.

C10AB - Fibrates

Clofibrate and analogues are classified here.

The DDD for fenofibrate is based on the micronised formulation.

C10AB01 - Clofibrate
StärkeAdm.RouteNote
 O 
2025 ©ywesee GmbH
Einstellungen | Hilfe | FAQ | Anmeldung | Kontakt | Home